Stock Price Forecast

March 21, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Acasti Pharma Inc chart...

About the Company

Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with severe HTG.

CEO

Janelle D'Alvise

Exchange

NASDAQ

Website

www.acastipharma.com

$-2M

Total Revenue

3

Employees

$23M

Market Capitalization

-2.27

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ACST News

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

8d ago, source: Yahoo Finance

2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing ...

Acasti Pharma Recognizes Rare Disease Day

22d ago, source: Yahoo

LAVAL, QC, Feb. 28, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug ...

Acasti Pharma Inc.

23d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference

14d ago, source: Morningstar

Get 7 Days Free Sign In Sign In Topics ...

Acasti Pharma Inc - Ordinary Shares - Class A

23d ago, source: U.S. News & World Report

A yield-curve inversion is often cited as a signal of recession, but its role in investment planning can be murkier.

Acasti: Fiscal Q3 Earnings Snapshot

1mon ago, source: Houston Chronicle

LAVAL, Quebec (AP) — LAVAL, Quebec (AP) — Acasti Pharma Inc. (ACST) on Tuesday reported a loss of $3.9 million in its fiscal third quarter. The Laval, Quebec-based company said it had a loss ...

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange | Morningstar

9d ago, source: Morningstar

Get 7 Days Free Sign In Sign In Topics ...

Acasti Pharma Recognizes Rare Disease Day

22d ago, source: Mena FN

(MENAFN- PR Newswire) LAVAL, QC, Feb. 28, 2023 /PRNewswire/ -- Acasti Pharma Inc. ('Acasti' or the 'Company') (NASDAQ: acst and TSX-V: ACST), a late-stage, specialty ...

Acasti Pharma Inc (ACST)

1mon ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

9d ago, source: Benzinga.com

LAVAL, Québec, March 13, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") ACSTACST a late-stage, specialty pharma company advancing three clinical stage drug candidates ...

Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange

9d ago, source: Stockhouse

LAVAL, Québec, March 13, 2023 /PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST and TSX-V: ACST) a late-stage, specialty pharma company advancing three clinical stage drug ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...